AB Corporate Bond ETF (NASDAQ:EYEG) Short Interest Update

AB Corporate Bond ETF (NASDAQ:EYEG) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,040 shares, an increase of 1,233.3% from the August 15th total of 78 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily volume of 668 shares, the short-interest ratio is currently 1.6 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in AB Corporate Bond ETF stock. Kestra Advisory Services LLC acquired a new position in shares of AB Corporate Bond ETF (NASDAQ:EYEG) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 951 shares of the specialty pharmaceutical company’s stock, valued at approximately $34,000. Kestra Advisory Services LLC owned 0.13% of AB Corporate Bond ETF at the end of the most recent reporting period. 64.16% of the stock is currently owned by institutional investors.

AB Corporate Bond ETF Trading Down 0.4%

AB Corporate Bond ETF stock traded down $0.15 during trading on Thursday, hitting $34.11. The company’s stock had a trading volume of 14 shares, compared to its average volume of 300. The stock has a market capitalization of $27.29 million, a price-to-earnings ratio of -20.30 and a beta of 0.18. The stock’s fifty day moving average is $34.64 and its 200 day moving average is $35.09. AB Corporate Bond ETF has a 1-year low of $34.01 and a 1-year high of $36.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07.

AB Corporate Bond ETF Cuts Dividend

The firm also recently declared a monthly dividend, which was paid on Friday, September 4th. Shareholders of record on Tuesday, September 1st were issued a $0.1284 dividend. The ex-dividend date was Tuesday, September 1st. This represents a c) annualized dividend and a yield of 4.5%. AB Corporate Bond ETF’s payout ratio is -101.79%.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.